EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Immunotherapy-induced Felty syndrome in a patient with metastatic melanoma

Laura S Park, Caoimhe Byrne, Hayley Burridge, Wendy Zhu, Michelle Leech, Miles C Andrews

Frontiers in Oncology · 20.04.2026 · 16

DOI: 10.3389/fonc.2026.1808710 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 20.04.2026. Verfasst von Laura S Park und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Alfred Health, Melbourne, VIC, Australia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) are critical in the modern treatment of advanced melanoma but can provoke immune-related adverse events (irAEs) with increased risk in patients having pre-existing autoimmune conditions. We present a case of Felty syndrome (FS) recurrence precipitated by a single dose of combination nivolumab plus relatlimab immunotherapy in a 71-year-old man with metastatic melanoma and a history of seropositive rheumatoid arthritis (RA) diagnosed several years earlier in the context of spontaneous FS. Following ICI, he presented with a neutrophil count of 0.0 cells/µL but without clinically active synovitis. He was promptly managed with intravenous methylprednisolone and methotrexate with rapid neutrophil recovery despite the ICI precipitant. In this report, we explore the differential diagnoses and treatment considerations, which highlight the importance of considering ICI-induced FS as a differential diagnosis in patients with a history of RA presenting with neutropenia. Early identification and collaborative care are vital for preventing life-threatening complications associated with neutropenia in this vulnerable patient population.

Schlagwörter

Stichwörter der Autor:innen

Felty syndromecase reportimmune-related adverse eventsimmunotherapymelanomarheumatoid arthritis

Autor:innen und Institutionen

  • Medical Oncology, Alfred Health, Melbourne, VIC, Australia.
  • Department of Rheumatology, Monash Health, Clayton, VIC, Australia.
  • Faculty of Medicine Nursing and Health Sciences, Monash University, Clayton, VIC, Australia.
  • Department of Cancer Medicine, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.

Zitieren

APA

Park, L. S., Byrne, C., Burridge, H., Zhu, W., Leech, M., & Andrews, M. C. (2026). Case Report: Immunotherapy-induced Felty syndrome in a patient with metastatic melanoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1808710

Vancouver

Park LS, Byrne C, Burridge H, Zhu W, Leech M, Andrews MC. Case Report: Immunotherapy-induced Felty syndrome in a patient with metastatic melanoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1808710

BibTeX
@article{Park2026,
  author = {Park, Laura S and Byrne, Caoimhe and Burridge, Hayley and Zhu, Wendy and Leech, Michelle and Andrews, Miles C},
  title = {Case Report: Immunotherapy-induced Felty syndrome in a patient with metastatic melanoma},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1808710}
}
Kostenlos starten →